


- **Alzheimer's disease (AD)** is particularly devastating since there is no cure, no way to prevent it and no proven way to slow its progression.
- Currently, approximately **18 million people** worldwide are afflicted with this disease and it is projected to reach over **30 million** by 2025.
- **Novel strategy** for symptomatic & disease-modifying treatment of Alzheimer's disease hitting two independent but synergistic pathways: epigenetic (HDAC) and non-epigenetic (PDE5, over-expressed in the brain of AD patients)<sup>1</sup>.
- Novel **proprietary compounds, first-in class dual inhibitors (HDAC and PDE5)**<sup>2</sup> show safety and efficacy in reversing AD phenotype using transgenic mice (APP/PS1, Tg2576)<sup>3</sup>.

## There is an imperative need to explore new therapeutic targets in Alzheimer's disease

### Hypothesis: Targets proposal


- ✓ By repressing gene transcription, HDAC2 plays a relevant role in memory function whereas HDAC6 is involved in axonal transport and protein aggregation.
- ✓ HDAC2 and HDAC6 are over-expressed in post-mortem brains of AD patients<sup>4,5</sup>.
- ✓ PDE5 is over-expressed in post-mortem brains of AD patients, and levels of its substrate cGMP are reduced in CSF from AD patients<sup>1</sup>.



## Simultaneous inhibition of several targets is a strategy to attain synergistic efficacy and to improve safety profile

### Hypothesis validation (proof of concept)

- ✓ Simultaneous inhibition of HDAC and PDE5 with reference compounds leads to a synergistic effect in AD models<sup>6</sup>



## CM-414 is a lead compound of a first-in-class chemical series that simultaneously inhibits class I HDAC, HDAC6 and PDE5<sup>3</sup>


### Product profile

- ✓ CM-414 has strong HDAC6 and PDE5 activity (IC<sub>50</sub> values < 100 nM) (A).
- ✓ CM-414 has a **moderate** class I activity (IC<sub>50</sub> 300-400 nM) to **minimize potential toxicity** associated to HDAC class I inhibition (A).
- ✓ CM-414 shows **functional effect** in neuronal culture, 10 nM for AcH3 and 100 nM for pCREB (B).
- ✓ CM-414 shows adequate ADME and pharmacokinetic profiles. The **half-life** (2.8 h) is optimal to trigger gene transcription avoiding sustained targets inhibitions.
- ✓ CM-414 **crosses BBB**, at a safe dose for chronic treatment, and shows *in vivo* functional response (histone acetylation and CREB phosphorylation) at brain level (C).
- ✓ CM-414 has an adequate therapeutic window, >2.7 log units.

## CM-414 shows a sustained efficacy in AD animal models suggesting a disease modifying mechanism<sup>3</sup>

### Preclinical assays

- ✓ CM-414 rescues impairment of Long-Term Potentiation (LTP) in APP/PS1 hippocampal slices (D)
- ✓ CM-414 (3-weeks of treatment) restores memory deficits in aged-AD Tg2576 mice (E, F)
- ✓ The **memory recovery** induced by CM-414 was maintained after a washout period of **4 weeks** in aged Tg2576 mice (G)
- ✓ Analysis of AD pathological marks in treated Tg2576 mice showed **significant decrease in amyloid and Tau pathology** (I).
- ✓ CM-414 treatment **reverts spine density loss** in the hippocampus of Tg2576 mice (J).



### Intellectual Property

Strong IP position: WO2014131855, WO2016020307 and WO2016030345 (4 different chemical series)

### Papers

<sup>1</sup>Ugarte A. et al. *Neuropathol Appl Neurobiol.* **2015**, *41*, 471; <sup>2</sup>Rabal et al., *J Med Chem* 2016 59: 8967-9004 <sup>3</sup>Cuadrado-Tejedor M., et al. *Neuropsychopharmacology* 2017 42: 524-539 <sup>4</sup>Gräff et al. *Nature* **2012**, 483 (7388); Ding et al. *J. Neurochem* **2008**, 106 (5); <sup>6</sup>Cuadrado-Tejedor M., et al. *Clin Epigenetics.* **2015**, 7:108.